Therefore, new strategies are under clinical development such as new targeted therapies such as ruxolitinib, a JAK 1-2 multicytokine receptor inhibitors [35] or drugs that block IL-1 (especially in the context of MAS [1, 33, 36]) or IL-6 [36]. The gene discussed is IL6; the disease is macrophage activation syndrome.